Sarah Cavanaugh - 08 Dec 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP of Corp Affairs & Admin.
Signature
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
Issuer symbol
CLDX
Transactions as of
08 Dec 2021
Net transactions value
-$219,439
Form type
4
Filing time
10 Dec 2021, 15:03:18 UTC
Previous filing
03 Nov 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $16,744 +1,857 +455% $9.02 2,265 08 Dec 2021 Direct
transaction CLDX Common Stock Options Exercise $56,737 +5,466 +241% $10.38 7,731 08 Dec 2021 Direct
transaction CLDX Common Stock Sale $292,920 -7,323 -95% $40.00 408 08 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -1,857 -14% $0.000000 11,458 08 Dec 2021 Common Stock 1,857 $9.02 Direct F2
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -5,466 -6.5% $0.000000 78,534 08 Dec 2021 Common Stock 5,466 $10.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
F2 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.